Clinical Trial Update: A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD) [Phase 2]

View source ↗

Summary

Bepranemab (UCB0107) was studied in a Phase 2 trial for efficacy, safety, and tolerability in patients with mild cognitive impairment or mild Alzheimer's diseas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• Bepranemab (Bepranemab)

Snippet

Sponsor: UCB Biopharma SRL | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED